Here are five takeaways:
1. Zimmer Biomet will not receive proceeds of the sale.
2. All of the proceedings will go to those stockholders.
3. Following the offering, Zimmer Biomet plans to buy $250 million common shares from Barclays Capital.
4. Zimmer Biomet will use the cash on hand to pay for the purchasing from the Blackstone and Goldman Sachs affiliates.
5. The company has spent nearly $165 million on repurchasing its shares this year.
More articles on devices:
Brian Ennis becomes president of Implanet America: 5 key notes
Healthmark introduces new Distal Soak
Smith & Nephew, Zimmer Biomet, Medovex & more: 20 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
